Insight Molecular Diagnostics (IMDX) Research & Development (2015 - 2026)

Insight Molecular Diagnostics has reported Research & Development for 12 years, with the latest figure at $2.4 million in Q1 2026.

• Quarterly Research & Development fell 17.85% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (up 13.86% YoY) and the FY2025 annual result came in at $15.9 million, up 61.6% from the prior year.
• Research & Development fell to $2.4 million in Q1 2026 per IMDX's latest filing, from $5.8 million in the prior quarter.
• Over five years, Research & Development peaked at $7.1 million in Q4 2024 and troughed at -$4.0 million in Q4 2023.
• A 5-year average of $1.8 million and a median of $1.4 million in 2022 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 533.86% in 2023, down 386.79% in 2023.
• Over 5 years, Research & Development stood at $1.4 million in 2022, then slumped by 386.79% to -$4.0 million in 2023, then jumped by 279.58% to $7.1 million in 2024, then dropped by 17.87% to $5.8 million in 2025, then slumped by 58.79% to $2.4 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $2.4 million, $5.8 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.